Clinical Trials Browser

Phase 2 × ruxolitinib × Plasma cell × Clear all

NCT00639002 2018-02-13

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Phase 2 Completed

13 enrolled 7 charts

Multiple Myeloma